phenprocoumon 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
anticoagulants, dicoumarol derivatives	2138	435-97-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: phenprocoumon fencumar marcoumar phenprocoumarol phenprocoumarole liquamar	Coumarin derivative that acts as a long acting oral anticoagulant. Molecular weight: 280.32 Formula: C18H16O3 CLOGP: 4.71 LIPINSKI: 0 HAC: 3 HDO: 1 TPSA: 46.53 ALOGS: -3.76 ROTB: 3 Status: OFM Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

phenprocoumon
fencumar
marcoumar
phenprocoumarol
phenprocoumarole
liquamar

Coumarin derivative that acts as a long acting oral anticoagulant.

Molecular weight: 280.32
Formula: C18H16O3
CLOGP: 4.71
LIPINSKI: 0
HAC: 3
HDO: 1
TPSA: 46.53
ALOGS: -3.76
ROTB: 3

Status: OFM

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
3	mg	O

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	1.43 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	0.20 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	0.02 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.57 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	126 hours	Lombardo F, Berellini G, Obach RS
S (Water solubility)	0.01 mg/mL	Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
Dec. 30, 1957	FDA	ORGANON USA INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
General physical health deterioration	282.35	26.97	205	6534	201197	63281086
Product monitoring error	250.01	26.97	64	6675	4452	63477831
Product prescribing error	240.02	26.97	94	6645	26195	63456088
Haematochezia	127.13	26.97	76	6663	53468	63428815
Anaemia	121.19	26.97	152	6587	293278	63189005
Haematoma	119.62	26.97	63	6676	34757	63447526
Acute kidney injury	112.80	26.97	139	6600	263276	63219007
Atrial fibrillation	101.36	26.97	90	6649	116546	63365737
Labelled drug-drug interaction medication error	98.35	26.97	41	6698	13358	63468925
Cardiac failure	87.98	26.97	74	6665	89068	63393215
Drug interaction	83.94	26.97	112	6627	229019	63253264
International normalised ratio increased	78.00	26.97	53	6686	46372	63435911
Drug ineffective	70.75	26.97	13	6726	1044752	62437531
Therapeutic drug monitoring analysis not performed	69.14	26.97	18	6721	1334	63480949
Fall	66.07	26.97	135	6604	392199	63090084
Pallor	63.82	26.97	40	6699	30528	63451755
Electrocardiogram abnormal	63.72	26.97	27	6712	9152	63473131
Prothrombin time prolonged	62.65	26.97	27	6712	9537	63472746
Bradycardia	56.67	26.97	53	6686	73174	63409109
Device stimulation issue	55.17	26.97	9	6730	59	63482224
Arrhythmia	49.00	26.97	37	6702	38103	63444180
Systemic infection	47.22	26.97	18	6721	4642	63477641
Dehydration	46.22	26.97	73	6666	173281	63309002
Skin haemorrhage	45.59	26.97	22	6717	10072	63472211
Gastrointestinal haemorrhage	43.17	26.97	48	6691	81128	63401155
Painful respiration	40.37	26.97	14	6725	2760	63479523
Shock haemorrhagic	40.01	26.97	20	6719	9875	63472408
Foetal chromosome abnormality	39.89	26.97	6	6733	21	63482262
Syncope	37.78	26.97	54	6685	117331	63364952
Upper gastrointestinal haemorrhage	37.66	26.97	24	6715	18828	63463455
Eosinophilic granulomatosis with polyangiitis	35.56	26.97	12	6727	2180	63480103
Dyspnoea	35.35	26.97	151	6588	661162	62821121
Faecaloma	34.93	26.97	17	6722	7924	63474359
Vitamin K deficiency	33.20	26.97	8	6731	432	63481851
Circulatory collapse	32.04	26.97	23	6716	21915	63460368
Epistaxis	31.97	26.97	39	6700	72686	63409597
Rash	31.88	26.97	10	6729	560861	62921422
Pulmonary vein occlusion	31.41	26.97	6	6733	105	63482178
Urogenital haemorrhage	31.34	26.97	7	6732	270	63482013
Cerebral haemorrhage	31.27	26.97	26	6713	30703	63451580
Coagulopathy	31.06	26.97	22	6717	20522	63461761
International normalised ratio abnormal	30.75	26.97	12	6727	3292	63478991
Lactic acidosis	30.15	26.97	28	6711	38259	63444024
Vascular graft infection	29.05	26.97	5	6734	47	63482236
Dizziness	28.40	26.97	105	6634	429820	63052463
Labelled drug-food interaction medication error	28.39	26.97	6	6733	178	63482105
Tachycardia	27.72	26.97	47	6692	118109	63364174
Angina pectoris	27.64	26.97	24	6715	30054	63452229
Dysmorphism	27.39	26.97	10	6729	2286	63479997
Fracture	27.38	26.97	20	6719	19564	63462719
International normalised ratio decreased	27.17	26.97	12	6727	4489	63477794

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Product prescribing error	197.48	21.16	105	9475	22822	34924529
General physical health deterioration	158.56	21.16	185	9395	128084	34819267
Product monitoring error	149.08	21.16	53	9527	4328	34943023
International normalised ratio abnormal	127.47	21.16	44	9536	3291	34944060
Contraindicated product administered	92.39	21.16	63	9517	21418	34925933
Rectal prolapse	90.24	21.16	22	9558	470	34946881
Renal cyst haemorrhage	84.53	21.16	22	9558	617	34946734
Intestinal haemorrhage	81.28	21.16	32	9548	3464	34943887
Intraductal papillary mucinous neoplasm	78.48	21.16	20	9560	515	34946836
Haematoma	69.55	21.16	57	9523	25548	34921803
SARS-CoV-2 antibody test positive	67.89	21.16	17	9563	407	34946944
Dizziness	66.84	21.16	169	9411	218352	34728999
Vena cava injury	66.44	21.16	16	9564	324	34947027
Abdominal wall haemorrhage	65.45	21.16	17	9563	473	34946878
Carotid arteriosclerosis	61.39	21.16	22	9558	1836	34945515
Blood glucose fluctuation	60.36	21.16	27	9553	4017	34943334
Vascular anastomotic haemorrhage	58.63	21.16	14	9566	273	34947078
International normalised ratio increased	57.80	21.16	68	9512	47259	34900092
Delayed graft function	57.56	21.16	22	9558	2199	34945152
Oedema peripheral	57.36	21.16	111	9469	119701	34827650
Aortic dilatation	55.53	21.16	19	9561	1382	34945969
Haematochezia	55.40	21.16	66	9514	46468	34900883
Perineal cyst	54.18	21.16	13	9567	259	34947092
Spinal stenosis	53.55	21.16	27	9553	5242	34942109
Actinic keratosis	51.14	21.16	25	9555	4542	34942809
Blood glucose abnormal	50.44	21.16	27	9553	5925	34941426
Vascular compression	50	21.16	13	9567	363	34946988
Mean cell volume increased	50.00	21.16	22	9558	3147	34944204
Hyperparathyroidism secondary	49.68	21.16	18	9562	1550	34945801
Respiratory tract haemorrhage	49.47	21.16	17	9563	1253	34946098
Cardiac failure	49.21	21.16	89	9491	91159	34856192
Platelet dysfunction	48.63	21.16	12	9568	270	34947081
Aortic arteriosclerosis	47.83	21.16	24	9556	4612	34942739
Renal artery stenosis	46.68	21.16	19	9561	2242	34945109
Dyspnoea	46.60	21.16	215	9365	376567	34570784
Electrolyte imbalance	45.36	21.16	35	9545	14377	34932974
Diverticulum intestinal	44.99	21.16	22	9558	3999	34943352
Hepatosplenomegaly	44.24	21.16	22	9558	4147	34943204
Abnormal clotting factor	44.23	21.16	9	9571	80	34947271
Syncope	42.84	21.16	84	9496	91367	34855984
Drug ineffective	41.09	21.16	39	9541	456712	34490639
Intervertebral disc space narrowing	40.62	21.16	14	9566	1041	34946310
Gastrointestinal haemorrhage	39.91	21.16	80	9500	88397	34858954
Blood 25-hydroxycholecalciferol decreased	39.18	21.16	10	9570	259	34947092
Gamma-glutamyltransferase increased	39.03	21.16	44	9536	29187	34918164
Spinal osteoarthritis	38.99	21.16	25	9555	7658	34939693
Swelling of eyelid	36.12	21.16	13	9567	1098	34946253
Arrhythmia	34.95	21.16	46	9534	35762	34911589
Restless legs syndrome	34.71	21.16	24	9556	8330	34939021
Basal cell carcinoma	34.07	21.16	34	9546	19624	34927727
Activated partial thromboplastin time prolonged	33.84	21.16	24	9556	8671	34938680
Squamous cell carcinoma of skin	33.31	21.16	26	9554	10855	34936496
Fall	32.94	21.16	126	9454	202759	34744592
Renal failure	32.75	21.16	94	9486	130463	34816888
Benign prostatic hyperplasia	32.66	21.16	29	9551	14466	34932885
Therapeutic drug monitoring analysis not performed	31.84	21.16	10	9570	555	34946796
Urinary incontinence	31.53	21.16	32	9548	18842	34928509
Left ventricular hypertrophy	30.63	21.16	22	9558	8108	34939243
JC virus CSF test positive	30.28	21.16	7	9573	118	34947233
Vitamin D decreased	30.10	21.16	16	9564	3460	34943891
Prothrombin time abnormal	29.08	21.16	10	9570	738	34946613
Spontaneous haemorrhage	28.20	21.16	8	9572	312	34947039
Glycosylated haemoglobin increased	28.15	21.16	24	9556	11336	34936015
Language disorder	27.22	21.16	13	9567	2243	34945108
C-reactive protein increased	26.90	21.16	51	9529	54047	34893304
Bradycardia	26.87	21.16	62	9518	75356	34871995
Large intestine polyp	26.62	21.16	20	9560	7894	34939457
Nocturia	26.18	21.16	22	9558	10188	34937163
Implant site inflammation	25.63	21.16	6	9574	107	34947244
Dyspnoea exertional	25.60	21.16	44	9536	43235	34904116
Vertigo	25.21	21.16	33	9547	25503	34921848
Cognitive disorder	25.16	21.16	35	9545	28658	34918693
Anaemia	24.99	21.16	128	9452	233207	34714144
Mean cell haemoglobin concentration	24.93	21.16	5	9575	41	34947310
Febrile neutropenia	24.61	21.16	4	9576	136845	34810506
Off label use	24.41	21.16	49	9531	419475	34527876
Soft tissue haemorrhage	23.98	21.16	6	9574	143	34947208
Haemorrhoids	23.05	21.16	24	9556	14551	34932800
Nail bed inflammation	22.92	21.16	6	9574	172	34947179
Contusion	22.87	21.16	38	9542	36326	34911025
Circulatory collapse	22.04	21.16	28	9552	21010	34926341
Prothrombin level decreased	21.65	21.16	9	9571	1119	34946232
Haemorrhage	21.42	21.16	45	9535	51325	34896026
Arteriosclerosis	21.29	21.16	21	9559	11947	34935404

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Product prescribing error	434.87	20.75	198	14941	44615	79684634
General physical health deterioration	405.92	20.75	368	14771	274870	79454379
Product monitoring error	372.39	20.75	115	15024	8791	79720458
Haematochezia	171.07	20.75	138	15001	87507	79641742
Haematoma	157.82	20.75	107	15032	52088	79677161
International normalised ratio abnormal	142.24	20.75	50	15089	5718	79723531
International normalised ratio increased	133.59	20.75	118	15021	84603	79644646
Anaemia	123.51	20.75	265	14874	444750	79284499
Drug ineffective	95.88	20.75	43	15096	1080870	78648379
Labelled drug-drug interaction medication error	93.97	20.75	61	15078	27589	79701660
Renal cyst haemorrhage	90.80	20.75	22	15117	670	79728579
Therapeutic drug monitoring analysis not performed	89.40	20.75	27	15112	1909	79727340
Atrial fibrillation	87.43	20.75	144	14995	197742	79531507
Arrhythmia	84.12	20.75	79	15060	61193	79668056
Drug interaction	83.24	20.75	218	14921	414965	79314284
Cardiac failure	79.88	20.75	121	15018	154721	79574528
Dizziness	78.99	20.75	249	14890	526192	79203057
Bradycardia	78.70	20.75	112	15027	135445	79593804
Intraductal papillary mucinous neoplasm	77.82	20.75	20	15119	778	79728471
Syncope	75.79	20.75	128	15011	179321	79549928
Gastrointestinal haemorrhage	75.58	20.75	115	15024	147604	79581645
Dyspnoea	73.60	20.75	339	14800	856686	78872563
SARS-CoV-2 antibody test positive	73.50	20.75	17	15122	422	79728827
Vena cava injury	71.73	20.75	16	15123	336	79728913
Rectal prolapse	65.86	20.75	22	15117	2156	79727093
Abdominal wall haemorrhage	65.76	20.75	17	15122	677	79728572
Fall	65.31	20.75	222	14917	487407	79241842
Vascular anastomotic haemorrhage	63.75	20.75	14	15125	273	79728976
Actinic keratosis	62.63	20.75	28	15111	6014	79723235
Prothrombin time prolonged	61.67	20.75	39	15100	16860	79712389
Oedema peripheral	61.61	20.75	143	14996	252145	79477104
Carotid arteriosclerosis	61.59	20.75	22	15117	2634	79726615
Electrolyte imbalance	60.96	20.75	49	15090	30832	79698417
Perineal cyst	59.07	20.75	13	15126	256	79728993
Aortic dilatation	57.58	20.75	19	15120	1793	79727456
Delayed graft function	55.63	20.75	22	15117	3485	79725764
Arthralgia	54.98	20.75	20	15119	571783	79157466
Pallor	54.69	20.75	57	15082	50005	79679244
Circulatory collapse	52.51	20.75	49	15090	37619	79691630
Aortic arteriosclerosis	52.28	20.75	28	15111	8890	79720359
Intestinal haemorrhage	51.74	20.75	25	15114	6401	79722848
Respiratory tract haemorrhage	49.56	20.75	17	15122	1806	79727443
Vascular compression	49.28	20.75	13	15126	561	79728688
Renal failure	48.03	20.75	113	15026	200855	79528394
Platelet dysfunction	47.64	20.75	12	15127	430	79728819
Hyperparathyroidism secondary	46.84	20.75	18	15121	2642	79726607
Spinal stenosis	46.80	20.75	32	15107	15759	79713490
Renal artery stenosis	45.48	20.75	19	15120	3463	79725786
Benign prostatic hyperplasia	45.40	20.75	28	15111	11584	79717665
Electrocardiogram abnormal	45.11	20.75	32	15107	16705	79712544
Spontaneous haemorrhage	44.73	20.75	13	15126	804	79728445
Hepatosplenomegaly	44.05	20.75	22	15117	6047	79723202
Mean cell volume increased	43.43	20.75	22	15117	6231	79723018
Haematuria	41.57	20.75	58	15081	68778	79660471
Orthostatic intolerance	41.10	20.75	15	15124	1909	79727340
Gamma-glutamyltransferase increased	40.62	20.75	51	15088	54629	79674620
Activated partial thromboplastin time prolonged	40.20	20.75	28	15111	14200	79715049
Presyncope	40.00	20.75	44	15095	41010	79688239
Diverticulum intestinal	39.48	20.75	23	15116	8582	79720667
Blood 25-hydroxycholecalciferol decreased	39.16	20.75	10	15129	379	79728870
Acute kidney injury	38.97	20.75	198	14941	519206	79210043
Intervertebral disc space narrowing	38.83	20.75	14	15125	1721	79727528
Off label use	38.65	20.75	71	15068	907144	78822105
Dehydration	38.54	20.75	119	15020	248068	79481181
Blood loss anaemia	38.05	20.75	28	15111	15470	79713779
Rash	36.13	20.75	34	15105	578324	79150925
Drug intolerance	36.10	20.75	4	15135	264115	79465134
Squamous cell carcinoma of skin	35.92	20.75	26	15113	14007	79715242
Coagulopathy	35.79	20.75	39	15100	35967	79693282
Completed suicide	35.49	20.75	3	15136	245764	79483485
Abnormal clotting factor	35.13	20.75	8	15131	185	79729064
Blood glucose fluctuation	33.70	20.75	19	15120	6663	79722586
Shock haemorrhagic	33.70	20.75	29	15110	20031	79709218
Spinal osteoarthritis	33.70	20.75	27	15112	16900	79712349
Disorientation	33.67	20.75	50	15089	62726	79666523
Language disorder	33.65	20.75	15	15124	3199	79726050
Blood glucose abnormal	32.71	20.75	22	15117	10544	79718705
Overdose	32.07	20.75	92	15047	184114	79545135
Left ventricular hypertrophy	31.56	20.75	22	15117	11169	79718080
Abdominal discomfort	31.39	20.75	5	15134	250722	79478527
Anxiety	31.02	20.75	5	15134	248507	79480742
Product dose omission issue	30.85	20.75	5	15134	247532	79481717
Foetal chromosome abnormality	30.68	20.75	5	15134	16	79729233
Coagulation test abnormal	30.65	20.75	11	15128	1334	79727915
JC virus CSF test positive	30.45	20.75	7	15132	169	79729080
Skin haemorrhage	30.21	20.75	22	15117	11959	79717290
Right ventricular failure	29.77	20.75	29	15110	23468	79705781
Painful respiration	29.52	20.75	14	15125	3439	79725810
Tachycardia	29.23	20.75	87	15052	177681	79551568
Product use in unapproved indication	29.17	20.75	6	15133	250353	79478896
Prothrombin time abnormal	28.85	20.75	10	15129	1096	79728153
Upper gastrointestinal haemorrhage	28.22	20.75	37	15102	41343	79687906
Febrile neutropenia	28.05	20.75	5	15134	230994	79498255
Basal cell carcinoma	27.98	20.75	35	15104	37340	79691909
Blood potassium increased	27.86	20.75	31	15108	29244	79700005
Joint swelling	27.85	20.75	10	15129	288636	79440613
Restlessness	27.80	20.75	39	15100	46453	79682796
Hypersensitivity	27.22	20.75	8	15131	262231	79467018
Lactic acidosis	26.80	20.75	48	15091	70311	79658938
Mean cell haemoglobin concentration	26.55	20.75	5	15134	43	79729206
Melaena	26.41	20.75	44	15095	60846	79668403
Chronic kidney disease	26.31	20.75	46	15093	66108	79663141
Pulmonary vein occlusion	26.17	20.75	6	15133	143	79729106
Fracture	25.94	20.75	26	15113	21775	79707474
Restless legs syndrome	25.83	20.75	25	15114	20067	79709182
Nocturia	25.50	20.75	21	15118	13660	79715589
Labelled drug-food interaction medication error	25.32	20.75	6	15133	166	79729083
Swelling of eyelid	25.28	20.75	13	15126	3798	79725451
Hypertensive crisis	25.13	20.75	25	15114	20745	79708504
Prothrombin level decreased	24.99	20.75	10	15129	1634	79727615
Glycosylated haemoglobin increased	24.83	20.75	24	15115	19236	79710013
Systemic infection	24.80	20.75	18	15121	9734	79719515
Large intestine polyp	24.72	20.75	20	15119	12688	79716561
Toxic epidermal necrolysis	24.61	20.75	36	15103	44545	79684704
Vitamin K deficiency	24.61	20.75	8	15131	720	79728529
Hypotension	24.47	20.75	155	14984	440162	79289087
Prothrombin time shortened	24.31	20.75	12	15127	3216	79726033
Sinusitis	24.24	20.75	4	15135	195497	79533752
Pain	24.18	20.75	62	15077	703740	79025509
Stevens-Johnson syndrome	23.64	20.75	33	15106	39133	79690116
Eosinophilic granulomatosis with polyangiitis	22.89	20.75	12	15127	3648	79725601
Urinary incontinence	22.53	20.75	33	15106	40876	79688373
Implant site inflammation	22.46	20.75	6	15133	272	79728977
Small intestine polyp	22.22	20.75	4	15135	26	79729223
Contraindicated product administered	22.11	20.75	73	15066	157465	79571784
Faecaloma	22.08	20.75	18	15121	11546	79717703
Cardiorenal syndrome	21.87	20.75	9	15130	1580	79727669
Epistaxis	21.67	20.75	58	15081	111457	79617792
Complications of transplanted kidney	21.51	20.75	14	15125	6352	79722897
Headache	21.38	20.75	59	15080	653713	79075536
Renal impairment	21.16	20.75	72	15067	157711	79571538
Malaise	21.09	20.75	38	15101	489831	79239418
Febrile infection	21.01	20.75	11	15128	3335	79725914
International normalised ratio decreased	20.76	20.75	15	15124	8055	79721194

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	B01AA04	BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS ANTITHROMBOTIC AGENTS Vitamin K antagonists
FDA EPC	N0000175476	Vitamin K Antagonist
MeSH PA	D000925	Anticoagulants
MeSH PA	D006401	Hematologic Agents
FDA MoA	N0000175964	Vitamin K Inhibitors
CHEBI has role	CHEBI:50249	anticoagulants
CHEBI has role	CHEBI:50390	NAD(P)H dehydrogenase (quinone) inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Myocardial infarction	indication	22298006	DOID:5844
Thromboembolic disorder	indication	371039008
Thrombosis	indication	439127006
Prosthetic replacement of heart valve	off-label use	307279007

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	4.51	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Vitamin K epoxide reductase complex subunit 1	Enzyme	Q9BQB6	VKOR1_HUMAN	INHIBITOR	IC50	5.75	SCIENTIFIC LITERATURE	CHEMBL
Pol polyprotein	Enzyme		Q72874_9HIV1		Ki	6.10	CHEMBL
Vitamin K epoxide reductase complex subunit 1	Unclassified		VKOR1_RAT		Ki	6.70	CHEMBL

External reference:

ID	Source
4018525	VUID
N0000146847	NUI
D05457	KEGG_DRUG
4018525	VANDF
C0031444	UMLSCUI
CHEBI:50438	CHEBI
CHEMBL1465	ChEMBL_ID
CHEMBL16694	ChEMBL_ID
DB00946	DRUGBANK_ID
D010644	MESH_DESCRIPTOR_UI
54680692	PUBCHEM_CID
6839	IUPHAR_LIGAND_ID
247	INN_ID
Q08SIO485D	UNII
8150	RXNORM
002086	NDDF
59488002	SNOMEDCT_US

Pharmaceutical products:

None